Inventiva organizes an event for analysts and investors

Inventiva, a biopharmaceutical company specializing in the treatment of metabolic steatohepatitis (MASH), announced an event for analysts and investors on October 8, 2025, in New York City. This event, scheduled ahead of the results of the Phase 3 NATiV3 study in 2026, will highlight the company's lead drug, lanifibranor.

During the event, international experts and a patient representative will discuss developments in the field of MASH. Speakers will include Nezam Afdhal of Harvard Medical School and William Alazawi of Queen Mary University. The Inventiva team will discuss the strategic positioning of lanifibranor, current clinical data, and the objectives of the ongoing Phase 3 study. A recording of the event will be available online.